Please try another search
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Name | Age | Since | Title |
---|---|---|---|
Michael S. Poirier | 68 | 2016 | President, COO, CEO & Chairman |
Richard A. David | 64 | 2017 | Independent Director |
Kurt H. Kruger | 69 | 2017 | Independent Director |
Wayne Klohs | - | 2022 | Chair of Scientific Advisory Board |
Christopher Slapak | 65 | 2022 | Member of Scientific Advisory Board |
Stephen Neidle | - | 2022 | Member of Scientific Advisory Board |
Matthew E. Korenberg | 49 | 2020 | Independent Director |
Sidney W. Emery | 77 | 2020 | Independent Director |
Ira Eliot Ritter | 75 | 2020 | Director |
Patricia LoRusso | - | 2022 | Member of Scientific Advisory Board |
Michael S. Gordon | - | 2022 | Member of Scientific Advisory Board |
Anthony W. Tolcher | - | 2022 | Member of Scientific Advisory Board |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review